Table 1:
Characteristics of HIV-positive patients
| Characteristic | Patients for nadir CD4 analysis (N = 231) |
Patients for delta CD4 analysis (N = 139) |
|
|---|---|---|---|
| Age, years, median (IQR) | 43.0 (37.0–49.0) | 42.0 (36.5–48.0) | |
| Nadir CD4 cells/mm3 median (IQR) | 318.0 (192.0–486.0) | 260.3 (152.0–393.0) | |
| Nadir CD4 cells/mm3 (categorical) | < 200 | 60 (26.0%) | 52 (37.4%) |
| ≥ 200 | 171 (74.0%) | 87 (62.6%) | |
| Delta CD4 cells/mm3, median (IQR) | N/A | 187.0 (99.0–364.0) | |
| Delta CD4 cells/mm3 (categorical) | < 100 | N/A | 36 (25.9%) |
| 100–249 | N/A | 51 (36.7%) | |
| ≥ 250 | N/A | 52 (37.4%) | |
| Stage | Stage IA, IB | 27 (11.7%) | 16 (11.5%) |
| Stage IIA, IIB | 113 (48.9%) | 66 (47.5%) | |
| Stage IIIA, IIIB | 78 (33.8%) | 48 (34.5%) | |
| Stage IVA, IVB | 11 (4.8%) | 8 (5.8%) | |
| Missing | 2 (0.9%) | 1 (0.7%) | |
| Number of chemo cycles | 0 | 48 (20.8%) | 33 (23.7%) |
| 1 | 18 (7.8%) | 11 (7.9%) | |
| 2 | 16 (6.9%) | 7 (5.0%) | |
| 3 | 30 (13.0%) | 20 (14.4%) | |
| 4 | 62 (26.8%) | 34 (24.5%) | |
| 5 | 43 (18.6%) | 24 (17.3%) | |
| Missing | 14 (6.1%) | 10 (7.2%) | |
| Performance status (KPS*) | ≤ 80 | 50 (21.7%) | 33 (23.8%) |
| > 80 | 147 (63.6%) | 89 (64.0%) | |
| Missing | 34 (14.7%) | 17 (12.2%) | |
| Hemoglobin at baseline, gm/dl, median (IQR) | 10.5 (9.1–12.1) | 10.4 (9.1–12.1) | |
| RT dose, median EQD2 (IQR) | 78.0 (68.0–80.0) | 78.0 (64.0–80.0) | |
| Treatment modality | Chemo only | 1 (0.4%) | 1 (0.7%) |
| RT only | 62 (26.8%) | 43 (30.9%) | |
| Chemo & RT | 168 (72.7%) | 95 (68.3%) | |
| Treatment intent | Curative | 81 (35.1%) | 45 (32.4%) |
| Palliative | 149 (64.5%) | 94 (67.6%) | |
| Missing | 1 (0.4%) | 0 | |
| On ART# | 216 (93.5%) | 138 (99.3%) | |
| Median survival in days (IQR) | 633.0 (329.0–866.0) | 569.0 (313.0–863.0) | |
| Baseline CD4 cells/mm3** | 484.0 (335.5–629.5) | 494.0 (343.0–626.0) | |
| Baseline viral load*** | ≤ 400 | 137 (59.3) | 105 (75.5) |
| > 400 | 10 (4.3) | 5 (3.6) | |
| Missing | 84 (36.4) | 29 (20.9) |
#
ART: Antiretroviral therapy
*
KPS: Karnofsky Performance Status
**
CD4 cell count at the time closest to treatment initiation
***
Viral load at the time closest to cancer diagnosis